Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.
The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 3, 3, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Respiratory, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Rheumatoid Arthritis, Hepatocellular Carcinoma, Melanoma, Solid Tumor, Colorectal Cancer, Liver Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Cutaneous T-Cell Lymphoma, Extramammary Paget Disease (EMPD), Glioblastoma Multiforme (GBM), Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Leukemias, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurotoxicity Syndromes, Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Osteoarthritis Pain, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sezary Syndrome and Unspecified.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.
The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2018' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 3, 3, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Respiratory, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Rheumatoid Arthritis, Hepatocellular Carcinoma, Melanoma, Solid Tumor, Colorectal Cancer, Liver Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Cutaneous T-Cell Lymphoma, Extramammary Paget Disease (EMPD), Glioblastoma Multiforme (GBM), Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Leukemias, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurotoxicity Syndromes, Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Osteoarthritis Pain, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sezary Syndrome and Unspecified.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
Epeius Biotechnologies Corp
GlaxoSmithKline Plc
Humanigen Inc
Izana Bioscience Ltd
Mologen AG
Morphotek Inc
Sillajen Biotherapeutics
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
Bria-IMT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bria-OTS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate CSF2 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate GMCSF for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0070 + Immune Checkpoint Modulator - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gimsilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenzilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGN-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GMCSF for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OrienX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otilimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexastimogene devacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reximmune-C2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBPL-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STINGVAX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talimogene laherparepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
Featured News & Press Releases
Apr 10, 2018: BriaCell to Present Encouraging Clinical Data at AACR 2018
Apr 03, 2018: BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
Mar 21, 2018: Targeted Immunotherapy Treatment Shows Promise for Treating Advanced Stage Liver Tumors
Mar 15, 2018: Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
Feb 23, 2018: SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy
Feb 13, 2018: Cancer-Killing Virus Acts by Alerting Immune System
Feb 06, 2018: BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
Feb 05, 2018: BriaCell Presenting at Upcoming Cancer Conference
Jan 31, 2018: BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT
Jan 29, 2018: SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
Jan 25, 2018: Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences
Jan 03, 2018: BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
Dec 14, 2017: Izana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing Spondylitis
Nov 06, 2017: BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax
Oct 30, 2017: FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax in Patients with Advanced Breast Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
Epeius Biotechnologies Corp
GlaxoSmithKline Plc
Humanigen Inc
Izana Bioscience Ltd
Mologen AG
Morphotek Inc
Sillajen Biotherapeutics
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
Bria-IMT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bria-OTS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate CSF2 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate GMCSF for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-0070 + Immune Checkpoint Modulator - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gimsilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenzilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGN-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GMCSF for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OrienX-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otilimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexastimogene devacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reximmune-C2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBPL-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STINGVAX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talimogene laherparepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
Featured News & Press Releases
Apr 10, 2018: BriaCell to Present Encouraging Clinical Data at AACR 2018
Apr 03, 2018: BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
Mar 21, 2018: Targeted Immunotherapy Treatment Shows Promise for Treating Advanced Stage Liver Tumors
Mar 15, 2018: Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
Feb 23, 2018: SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy
Feb 13, 2018: Cancer-Killing Virus Acts by Alerting Immune System
Feb 06, 2018: BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
Feb 05, 2018: BriaCell Presenting at Upcoming Cancer Conference
Jan 31, 2018: BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT
Jan 29, 2018: SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
Jan 25, 2018: Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences
Jan 03, 2018: BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
Dec 14, 2017: Izana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing Spondylitis
Nov 06, 2017: BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax
Oct 30, 2017: FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax in Patients with Advanced Breast Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aduro BioTech Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by BriaCell Therapeutics Corp, H1 2018
Pipeline by Cold Genesys Inc, H1 2018
Pipeline by Epeius Biotechnologies Corp, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Humanigen Inc, H1 2018
Pipeline by Izana Bioscience Ltd, H1 2018
Pipeline by Mologen AG, H1 2018
Pipeline by Morphotek Inc, H1 2018
Pipeline by Sillajen Biotherapeutics, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aduro BioTech Inc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by BriaCell Therapeutics Corp, H1 2018
Pipeline by Cold Genesys Inc, H1 2018
Pipeline by Epeius Biotechnologies Corp, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Humanigen Inc, H1 2018
Pipeline by Izana Bioscience Ltd, H1 2018
Pipeline by Mologen AG, H1 2018
Pipeline by Morphotek Inc, H1 2018
Pipeline by Sillajen Biotherapeutics, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
Epeius Biotechnologies Corp
GlaxoSmithKline Plc
Humanigen Inc
Izana Bioscience Ltd
Mologen AG
Morphotek Inc
Sillajen Biotherapeutics
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aduro BioTech Inc
Amgen Inc
BriaCell Therapeutics Corp
Cold Genesys Inc
Epeius Biotechnologies Corp
GlaxoSmithKline Plc
Humanigen Inc
Izana Bioscience Ltd
Mologen AG
Morphotek Inc
Sillajen Biotherapeutics
